Abstract
The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Current HIV Research
Title:Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin
Volume: 10 Issue: 4
Author(s): Katy Janvier, Nicolas Roy and Clarisse Berlioz-Torrent
Affiliation:
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Abstract: The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Export Options
About this article
Cite this article as:
Janvier Katy, Roy Nicolas and Berlioz-Torrent Clarisse, Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792414
DOI https://dx.doi.org/10.2174/157016212800792414 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine Meet Our Editorial Board Member
Current Medical Imaging Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs
Current Drug Targets - Infectious Disorders Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Autophagy Fails to Alter Withaferin A-Mediated Lethality in Human Breast Cancer Cells
Current Cancer Drug Targets Structure and Function of HIV-1 Integrase
Current Topics in Medicinal Chemistry Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Current Medicinal Chemistry Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets